quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:16:26·76d
INSIDERFiling
Syndax Pharmaceuticals Inc. logo

Director Jarrett Jennifer was granted 24,000 shares, increasing direct ownership by 27% to 114,000 units (SEC Form 4)

SNDX· Syndax Pharmaceuticals Inc.
Health Care
Original source

Companies

  • SNDX
    Syndax Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Oct 16UpdateH.C. Wainwright$40.00
  • Sep 10UpdateStifel$44.00
  • Sep 4UpdateGuggenheim$34.00
  • Aug 5UpdateBTIG Research$56.00
  • Jul 10UpdateGoldman$18.00
  • Oct 24UpdateUBS$37.00

Related

  • PR20d
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Syndax Pharmaceuticals Inc.
  • PR50d
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • SEC56d
    SEC Form S-8 filed by Syndax Pharmaceuticals Inc.
  • SEC56d
    SEC Form 10-K filed by Syndax Pharmaceuticals Inc.
  • SEC56d
    Syndax Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR56d
    Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
  • PR59d
    Syndax Announces Participation in March Investor Conferences
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022